What are the treatment options for gout?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment Options for Gout

The first-line treatments for acute gout flares are NSAIDs at full anti-inflammatory doses, low-dose colchicine (1.2 mg followed by 0.6 mg one hour later), or oral corticosteroids (prednisone 30-35 mg daily for 3-5 days), with treatment initiated within 24 hours of symptom onset for optimal outcomes. 1, 2, 3

Acute Gout Attack Management

  • Colchicine is most effective when started within 12 hours of symptom onset using the low-dose regimen (1.2 mg followed by 0.6 mg one hour later) 1, 3
  • NSAIDs at full anti-inflammatory doses (e.g., naproxen 500 mg twice daily) are effective when started promptly 1, 2
  • Oral corticosteroids (prednisolone 30-35 mg daily for 3-5 days) are recommended for patients with contraindications to NSAIDs or colchicine 1, 3
  • Intra-articular corticosteroid injection is an effective option for single joint involvement 1, 2
  • For severe attacks involving multiple joints, combination therapy (e.g., colchicine with NSAIDs or colchicine with corticosteroids) can be considered 3
  • Topical ice application is recommended as an adjunctive measure during acute attacks 2

Special Considerations for Acute Treatment

  • Colchicine should be avoided in patients with severe renal impairment (GFR < 30 mL/min) 3, 4
  • In patients with severe renal impairment requiring colchicine, treatment courses should not be repeated more than once every two weeks 4
  • For patients undergoing dialysis, the total recommended dose for gout flares should be reduced to a single dose of 0.6 mg 4
  • Patients with severe hepatic impairment should not repeat colchicine treatment courses more than once every two weeks 4

Long-Term Management and Prevention

  • Xanthine oxidase inhibitors (allopurinol or febuxostat) are recommended as first-line options for long-term management of gout 1, 2, 5
  • Uricosuric agents (probenecid, benzbromarone) can be used as alternatives in patients with normal renal function 1, 5
  • The target serum urate level should be below 6 mg/dL 2, 5
  • Anti-inflammatory prophylaxis is strongly recommended when starting urate-lowering therapy to prevent flares, with options including: 1, 2
    • Low-dose colchicine (0.5-0.6 mg once or twice daily)
    • Low-dose NSAIDs with gastroprotection if indicated
    • Low-dose prednisone
  • Prophylaxis should continue for at least 6 months, or 3 months after achieving target serum urate if no tophi are present, or 6 months after achieving target serum urate if tophi are present 1, 2, 5

Lifestyle Modifications

  • Weight loss is recommended for obese patients 1, 2
  • Avoid alcoholic drinks, especially beer 2, 5
  • Avoid beverages sweetened with high-fructose corn syrup 2, 5
  • Limit consumption of purine-rich foods (e.g., organ meats, shellfish) 5
  • Encourage consumption of vegetables and low-fat or nonfat dairy products 5

Common Pitfalls and Caveats

  • Failing to start treatment early (within 24 hours) significantly reduces effectiveness 1, 2, 3
  • High-dose colchicine regimens cause significant gastrointestinal side effects, while low-dose regimens are equally effective with fewer adverse events 2, 3
  • Discontinuing urate-lowering therapy during acute flares should be avoided; continuing established therapy is now recommended 1, 2, 3
  • Inadequate duration of prophylaxis when initiating urate-lowering therapy often leads to breakthrough flares and poor medication adherence 1, 2
  • NSAIDs should be avoided in patients with heart failure, peptic ulcer disease, or significant renal disease 2
  • Drug interactions with colchicine should be carefully monitored, particularly with strong P-glycoprotein and/or CYP3A4 inhibitors such as cyclosporin or clarithromycin 3

References

Guideline

Acute and Chronic Gout Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment Options for Gout

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Gout Flare Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Diagnosis, treatment, and prevention of gout.

American family physician, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.